Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 1999, p. 259-263, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Thiocarboxanilide Nonnucleoside Inhibitor UC781 Restores
Antiviral Activity of 3'-Azido-3'-Deoxythymidine (AZT) against
AZT-Resistant Human Immunodeficiency Virus Type 1
Gadi
Borkow,
Dominique
Arion,
Mark A.
Wainberg, and
Michael A.
Parniak*
Lady Davis Institute for Medical Research and
McGill University AIDS Centre, Sir Mortimer B. Davis-Jewish General
Hospital, Montreal, Quebec H3T 1E2, Canada
Received 26 May 1998/Returned for modification 29 September
1998/Accepted 31 October 1998
N-[4-Chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furancarbothioamide
(UC781) is an exceptionally potent nonnucleoside inhibitor of human
immunodeficiency virus type 1 (HIV-1) reverse transcriptase. We found
that a 1:1 molar combination of UC781 and 3'-azido-3'-deoxythymidine
(AZT) showed high-level synergy in inhibiting the replication of
AZT-resistant virus, implying that UC781 can restore antiviral activity
to AZT against AZT-resistant HIV-1. Neither the nevirapine plus AZT nor
the
2',5'-bis-O-(t-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide plus AZT combinations had this effect. Studies with purified HIV-1 reverse transcriptase (from a wild type and an AZT-resistant mutant) showed that UC781 was a potent inhibitor of the pyrophosphorolytic cleavage of nucleotides from the 3' end of the DNA polymerization primer, a process that we have proposed to be critical for the phenotypic expression of AZT resistance. Combinations of UC781 plus AZT
did not act in synergy to inhibit the replication of either wild-type
virus or UC781-resistant HIV-1. Importantly, the time to the
development of viral resistance to combinations of UC781 plus AZT is
significantly delayed compared to the time to the development of
resistance to either drug alone.
*
Corresponding author. Mailing address: Lady Davis
Institute for Medical Research, 3755 Cote Ste-Catherine Rd., Montreal,
Quebec H3T 1E2, Canada. Phone: (514) 340-8260. Fax: (514) 340-7502. E-mail: mparniak{at}ldi.jgh.mcgill.ca.
Antimicrobial Agents and Chemotherapy, February 1999, p. 259-263, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Radzio, J., Sluis-Cremer, N.
(2008). Efavirenz Accelerates HIV-1 Reverse Transcriptase Ribonuclease H Cleavage, Leading to Diminished Zidovudine Excision. Mol. Pharmacol.
73: 601-606
[Abstract]
[Full Text]
-
Basavapathruni, A., Anderson, K. S.
(2007). Reverse transcription of the HIV-1 pandemic. FASEB J.
21: 3795-3808
[Abstract]
[Full Text]
-
Roth, S., Monsour, M., Dowland, A., Guenthner, P. C., Hancock, K., Ou, C.-Y., Dezzutti, C. S.
(2007). Effect of Topical Microbicides on Infectious Human Immunodeficiency Virus Type 1 Binding to Epithelial Cells. Antimicrob. Agents Chemother.
51: 1972-1978
[Abstract]
[Full Text]
-
Patton, D. L., Sweeney, Y. T. C., Balkus, J. E., Rohan, L. C., Moncla, B. J., Parniak, M. A., Hillier, S. L.
(2007). Preclinical Safety Assessments of UC781 Anti-Human Immunodeficiency Virus Topical Microbicide Formulations. Antimicrob. Agents Chemother.
51: 1608-1615
[Abstract]
[Full Text]
-
Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J., Olson, W. C.
(2006). Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1.. Antimicrob. Agents Chemother.
50: 3289-3296
[Abstract]
[Full Text]
-
Cruchaga, C., Anso, E., Rouzaut, A., Martinez-Irujo, J. J.
(2006). Selective Excision of Chain-terminating Nucleotides by HIV-1 Reverse Transcriptase with Phosphonoformate as Substrate. J. Biol. Chem.
281: 27744-27752
[Abstract]
[Full Text]
-
Hossain, M. M., Parniak, M. A.
(2006). In Vitro Microbicidal Activity of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) UC781 against NNRTI-Resistant Human Immunodeficiency Virus Type 1. J. Virol.
80: 4440-4446
[Abstract]
[Full Text]
-
Ambrose, Z., Boltz, V., Palmer, S., Coffin, J. M., Hughes, S. H., KewalRamani, V. N.
(2004). In Vitro Characterization of a Simian Immunodeficiency Virus-Human Immunodeficiency Virus (HIV) Chimera Expressing HIV Type 1 Reverse Transcriptase To Study Antiviral Resistance in Pigtail Macaques. J. Virol.
78: 13553-13561
[Abstract]
[Full Text]
-
Basavapathruni, A., Bailey, C. M., Anderson, K. S.
(2004). Defining a Molecular Mechanism of Synergy between Nucleoside and Nonnucleoside AIDS Drugs. J. Biol. Chem.
279: 6221-6224
[Abstract]
[Full Text]
-
Odriozola, L., Cruchaga, C., Andreola, M., Dolle, V., Nguyen, C. H., Tarrago-Litvak, L., Perez-Mediavilla, A., Martinez-Irujo, J. J.
(2003). Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase Inhibit Phosphorolysis and Resensitize the 3'-Azido-3'-deoxythymidine (AZT)-resistant Polymerase to AZT-5'-triphosphate. J. Biol. Chem.
278: 42710-42716
[Abstract]
[Full Text]
-
Girouard, M., Diallo, K., Marchand, B., McCormick, S., Gotte, M.
(2003). Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TC. J. Biol. Chem.
278: 34403-34410
[Abstract]
[Full Text]